Structure Therapeutics (GPCR) grants CSO new stock options and RSUs

Rhea-AI Filing Summary

Structure Therapeutics Inc. reported that Chief Scientific Officer Xichen Lin received new equity awards. Lin was granted an employee stock option for 53,703 ordinary shares at an exercise price of $16.82 per share, expiring on March 18, 2036. One quarter of these option shares will vest on March 1, 2027, with the remainder vesting in 36 equal monthly installments, subject to continued service.

Lin was also awarded 43,368 restricted stock units, each representing one ordinary share. These RSUs vest one quarter annually on each anniversary of March 1, 2026, subject to continued service. Following the RSU grant, Lin directly holds 228,960 ordinary shares. The company notes that each American Depositary Share represents three ordinary shares.

Insights

Equity compensation analyst

CSO receives routine option and RSU grants as equity compensation.

The filing shows Xichen Lin, Chief Scientific Officer of Structure Therapeutics, receiving an option over 53,703 ordinary shares at $16.82 plus 43,368 RSUs. Both awards vest over several years, contingent on continued service.

These are compensation-related acquisitions (Form 4 code A), not open-market purchases or sales. They increase Lin’s equity exposure and align incentives with shareholders but are typical for senior executives. The filing does not indicate any discretionary trading activity or pre-arranged 10b5-1 sales.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lin Xichen

(Last) (First) (Middle)

C/O STRUCTURE THERAPEUTICS INC.

601 GATEWAY BLVD., SUITE 900

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Structure Therapeutics Inc. [ GPCR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF SCIENTIFIC OFFICER

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/19/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares(1)	03/19/2026		A(2)		43,368	A	$0	228,960	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$16.82(3)	03/19/2026		A		53,703		(4)	03/18/2036	Ordinary Shares(1)	53,703	$0	53,703	D

Explanation of Responses:

1. The Ordinary Shares of the Issuer may be represented by American Depositary Shares ('ADSs"). Each ADS represents three Ordinary Shares of the Issuer.

2. Represents the grant of restricted stock units ("RSUs"), each of which represents a contingent right to receive one ordinary share of the Issuer. The RSUs vest 1/4th annually on each anniversary of March 1, 2026, subject to Reporting Person's continued service on such dates.

3. The option exercise price per share is equal to the fair market value per Ordinary Share on the grant date based on the trading price of the Issuer's ADSs.

4. 1/4th of the shares subject to the option shall vest March 1, 2027, and the remaining shares shall vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through each such vesting date.

	/s/ Jun Yoon, Attorney-in-Fact	03/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider equity awards did GPCR Chief Scientific Officer Xichen Lin receive?

Xichen Lin received an option over 53,703 ordinary shares at $16.82 per share and 43,368 restricted stock units. Both awards are compensation grants that vest over time, increasing Lin’s long-term ownership stake in Structure Therapeutics Inc. without any open-market share purchases.

How do the new stock options for GPCR’s CSO vest and when do they expire?

The option for 53,703 ordinary shares vests 25% on March 1, 2027, with the remaining shares vesting in 36 equal monthly installments thereafter. The option carries a $16.82 exercise price and expires on March 18, 2036, assuming continued service throughout vesting.

What are the vesting terms of the 43,368 RSUs granted to GPCR’s CSO?

The 43,368 restricted stock units each convert into one ordinary share upon vesting. They vest in four equal annual installments on each anniversary of March 1, 2026, conditioned on Xichen Lin’s continued service. This structure encourages multi-year retention and alignment with company performance.

How many Structure Therapeutics shares does Xichen Lin own after these Form 4 transactions?

After the RSU grant, Xichen Lin directly holds 228,960 ordinary shares of Structure Therapeutics Inc. This total reflects non-derivative holdings reported in the filing and does not include unexercised options or unvested RSUs, which represent additional potential future ownership if vesting conditions are met.

Are the GPCR equity awards to the CSO open-market purchases or compensation grants?

Both transactions are compensation grants, coded “A” as grant or award acquisitions, not open-market purchases. The option and RSU awards were issued at no cash cost per share on grant date and are subject to multi-year vesting, tying executive rewards to continued employment and company performance.

How are Structure Therapeutics ordinary shares related to its American Depositary Shares (ADSs)?

Each American Depositary Share of Structure Therapeutics represents three ordinary shares. The option grant and RSUs are denominated in ordinary shares, but investors trading ADSs on U.S. markets should remember this 3-to-1 ratio when comparing insider holdings to ADS counts and market quotations.